Emerging as a noteworthy advance in the fight against obesity, this medication is generating considerable attention . This treatment combines properties of two established GLP-1 receptor agonists, liraglutide, and an new glucose-dependent incretin component. Early patient data have indicated significant body loss in people with excessive weight, po